TY - GEN
T1 - Adrenaline autoinjector is under-prescribed in typical cold urticaria patients living in tropical climate countries
AU - Bizjak, Mojca
AU - Košnik, Mitja
AU - Dinevski, Dejan
AU - Francis Thomsen, Simon
AU - Fomina, Daria
AU - Borzova, Elena
AU - Kulthanan, Kanokvalai
AU - Meshkova, Raisa
AU - Aarestrup, FernandoM
AU - Melina Ahsan, Dalia
AU - Al-Ahmad, Mona
AU - Altrichter, Sabine
AU - Bauer, Andrea
AU - Brockstädt, Maxi
AU - Costa, Célia
AU - Demir, Semra
AU - Fachini Criado, Roberta
AU - Felipe Ensina, Luis
AU - Gelincik, Asli
AU - Giménez-Arnau, Ana Maria
AU - Gonçalo, Margarida
AU - Gotua, Maia
AU - Grønlund Holm, Jesper
AU - Inomata, Naoko
AU - Kasperska-Zajac, Alicja
AU - Khoshkhui, Maryam
AU - Klyucharova, Aliya
AU - Kocatürk, Emek
AU - Lu, Rongbiao
AU - Makris, Michael
AU - Maltseva, Natalya
AU - Pasali, Maria
AU - Paulino, Marisa
AU - Pesqué, David
AU - Peter, Jonny
AU - Dario Ramón, German
AU - Ritchie, Carla
AU - Oliveira Rodrigues Valle, Solange
AU - Rudenko, Michael
AU - Sikora, Agnieszka
AU - Wagner, Nicola
AU - Xepapadaki, Paraskevi
AU - Xue, Xiaoyang
AU - Zhao, Zuotao
AU - Terhorst-Molawi, Dorothea
AU - Maurer, Marcus
N1 - © 2022 Bizjak, Košnik, Dinevski, Thomsen, Fomina, Borzova, Kulthanan, Meshkova, Aarestrup, Ahsan, Al-Ahmad, Altrichter, Bauer, Brockstädt, Costa, Demir, Criado, Ensina, Gelincik, Giménez-Arnau, Gonçalo, Gotua, Holm, Inomata, Kasperska-Zajac, Khoshkhui, Klyucharova, Kocatürk, Lu, Makris, Maltseva, Pasali, Paulino, Pesqué, Peter, Ramón, Ritchie, Valle, Rudenko, Sikora,Wagner, Xepapadaki, Xue, Zhao, Terhorst-Molawi, Maurer [Author(s)], licensee HBKU Press.
PY - 2022
Y1 - 2022
N2 - Background: The diagnosis of typical cold urticaria (ColdU) relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). Till date, it is largely unclear how often patients with ColdU receive adrenaline treatment and are provided with an adrenaline autoinjector (AAI). Methods: An international, cross-sectional study, COLD-CE (i.e., comprehensive evaluation of ColdU and other cold-induced reactions), was carried out at 32 UCAREs. Detailed histories were taken and CST with an ice cube and/or TempTest® performed. ColdA was defined as an acute cold-induced (i.e., by cold water, air, or surfaces) involvement of the skin and/or visible mucosal tissue and at least one of the symptoms (cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms). Results: Of the 551 ColdU patients, 75% (n = 412) had a positive CST. Of them, concomitant chronic spontaneous urticaria was diagnosed in 10%. Of 372 patients with stand-alone ColdU, 69% were women and 91% adults. Their median age was 36 (IQR 26 - 48) years. Patients were also categorized into residents of countries with a tropical (n = 33), temperate (n = 264), or cold (n = 75) climate (Table 1: R13C1, R17C1, R21C1). AAI was more often prescribed to residents of temperate than tropical countries (30% vs. 12%, p = .038; Table 1: R31C1), although the frequency of ColdA did not significantly differ between these countries (44% vs. 42%, p = 1.000; R29C2). Residents of tropical countries had a higher frequency of ColdA induced by cold air than residents of temperate (36% vs. 12%, p = .001; R29C4) or cold (36% vs. 12%, p = .007; R25C4) countries. Cardiovascular manifestations induced by cold air were diagnosed in 33% (n = 11) of residents of tropical countries, but only 18% (n = 2) and 36% (n = 4) of them had received adrenaline and AAI, respectively (R13 - 15C7). Furthermore, hypotension and/or loss of consciousness induced by cold air occurred in 18% (n = 6) of patients, but only 17% (n = 1) received adrenaline (R13 - 14C10). ColdA was induced by complete cold water immersion in 9% (n = 3) of patients, and none of them received adrenaline treatment nor AAI (R13 - 15C3). Conclusion: Our findings suggest that ColdA is undertreated and call for changes in ColdU management.
AB - Background: The diagnosis of typical cold urticaria (ColdU) relies on whealing in response to local cold stimulation testing (CST). It can also manifest with cold-induced anaphylaxis (ColdA). Till date, it is largely unclear how often patients with ColdU receive adrenaline treatment and are provided with an adrenaline autoinjector (AAI). Methods: An international, cross-sectional study, COLD-CE (i.e., comprehensive evaluation of ColdU and other cold-induced reactions), was carried out at 32 UCAREs. Detailed histories were taken and CST with an ice cube and/or TempTest® performed. ColdA was defined as an acute cold-induced (i.e., by cold water, air, or surfaces) involvement of the skin and/or visible mucosal tissue and at least one of the symptoms (cardiovascular manifestations, difficulty breathing, or gastrointestinal symptoms). Results: Of the 551 ColdU patients, 75% (n = 412) had a positive CST. Of them, concomitant chronic spontaneous urticaria was diagnosed in 10%. Of 372 patients with stand-alone ColdU, 69% were women and 91% adults. Their median age was 36 (IQR 26 - 48) years. Patients were also categorized into residents of countries with a tropical (n = 33), temperate (n = 264), or cold (n = 75) climate (Table 1: R13C1, R17C1, R21C1). AAI was more often prescribed to residents of temperate than tropical countries (30% vs. 12%, p = .038; Table 1: R31C1), although the frequency of ColdA did not significantly differ between these countries (44% vs. 42%, p = 1.000; R29C2). Residents of tropical countries had a higher frequency of ColdA induced by cold air than residents of temperate (36% vs. 12%, p = .001; R29C4) or cold (36% vs. 12%, p = .007; R25C4) countries. Cardiovascular manifestations induced by cold air were diagnosed in 33% (n = 11) of residents of tropical countries, but only 18% (n = 2) and 36% (n = 4) of them had received adrenaline and AAI, respectively (R13 - 15C7). Furthermore, hypotension and/or loss of consciousness induced by cold air occurred in 18% (n = 6) of patients, but only 17% (n = 1) received adrenaline (R13 - 14C10). ColdA was induced by complete cold water immersion in 9% (n = 3) of patients, and none of them received adrenaline treatment nor AAI (R13 - 15C3). Conclusion: Our findings suggest that ColdA is undertreated and call for changes in ColdU management.
U2 - 10.5339/qmj.2022.fqac.19
DO - 10.5339/qmj.2022.fqac.19
M3 - Conference article
C2 - 35909392
SN - 0253-8253
VL - 2022
SP - 19
JO - Qatar medical journal
JF - Qatar medical journal
IS - 2
ER -